drugset
drugset / Trial / NCT04973033

Effect of Tofacitinib in Treating ANCA-associated Vasculitis

NCT04973033 ↗

Completed 10 enrolled Shanghai Zhongshan Hospital
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to evaluate the efficacy and safety of tofacitinib 5 mg twice daily in AAV patients.

Timeline

Start
2019-12-01
Primary completion
2021-01-31
Completion
2021-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tofacitinib Small molecule 5 mg Oral

Indications

anti-neutrophil cytoplasmic antibody-associated vasculitis substance abuse